{
    "nct_id": "NCT06291220",
    "official_title": "A Phase 1 Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-453 in Adult Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
    "inclusion_criteria": "* Relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) that has received at least 2 prior systemic therapies and have no available (or established) therapies known to provide clinical benefit and to which the participant would consent to receiving.\n* Laboratory values meeting those listed in the protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* QT interval corrected for heart rate (QTc) using Fridericia's correction of > 470 msec (females) or > 450 msec (males), Grade 3 arrythmia, and/or other clinically significant cardiac abnormalities.\n* Known to be B-cell leukemia/lymphoma 2 inhibitor (BCL-2i) refractory or has received a BCL-2i-containing regimen within (6 months) of starting study drug (e.g., venetoclax, lisaftoclax, BGV-11417).\n* Has active human immunodeficiency virus (HIV) infection. HIV testing is not required unless required locally.\n* Recent history (within 6 months) of:\n\n  * Congestive heart failure (defined as New York Heart Association, Class 2 or higher).\n  * Ischemic cardiovascular event.\n  * Cardiac arrhythmia requiring pharmacological or surgical intervention.\n  * Pericardial effusion.\n  * Pericarditis.\n* Consumes known moderate or strong inhibitors of cytochrome P450 3A isoform subfamily (CYP3A) within 14 day or 5 half-lives of the drug (whichever is shorter) before the first dose of ABBV-453.",
    "miscellaneous_criteria": ""
}